Forty-eight week changes in quality of life and adherence in the MONET trial: darunavir/ritonavir (DRV/r) with and without nucleoside analogues (NRTIs) for patients with HIV RNA<50 copies/ml at screening

被引：0
|
作者：
Stephan, C. [1 ]
Arribas, J. [2 ]
Carosi, A. [3 ]
Hill, A. [4 ]
Anceau, A. [5 ]
Moecklinghoff, C. [6 ]
机构：
[1] Goethe Univ Frankfurt, Frankfurt, Germany
[2] Hosp La Paz, Madrid, Spain
[3] Inst Maattie Infett & Trop, Brescia, Italy
[4] Univ Liverpool, Pharmacol Res Labs, Liverpool L69 3BX, Merseyside, England
[5] Janssen Cilag, Issy Les Moulineaux, France
[6] Janssen Cilag EMEA, Neuss, Germany
来源：
ANTIVIRAL THERAPY | 2009年 / 14卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
引用
收藏
页码：A44 / A44
页数：1
相关论文
共 14 条
  • [1] Neuropsychiatric adverse events in the MONET trial: darunavir/ritonavir with and without nucleoside analogues for patients with HIV RNA<50 copies/ml at screening
    di Perri, G.
    Faetkenheuer, G.
    Hill, A.
    van Delft, Y.
    Moecklinghoff, C.
    ANTIVIRAL THERAPY, 2009, 14 (07) : A43 - A44
  • [2] Anthropometric sub-study of the MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA<50 copies/ml at screening
    Horban, A.
    Arribas, J.
    Hill, A.
    van Delft, Y.
    Moecklinghoff, C.
    ANTIVIRAL THERAPY, 2010, 15 (08) : A36 - A37
  • [3] The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml
    Arribas, Jose R.
    Horban, Andrzej
    Gerstoft, Jan
    Faetkenheuer, Gerdt
    Nelson, Mark
    Clumeck, Nathan
    Pulido, Federico
    Hill, Andrew
    van Delft, Yvon
    Stark, Thomas
    Moecklinghoff, Christiane
    AIDS, 2010, 24 (02) : 223 - 230
  • [4] Anthropometric sub-study of the MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA <50 copies/ml at screening
    Horban, A.
    Arribas, J.
    Hill, A.
    van Delft, Y.
    Moecklinghoffs, C.
    ANTIVIRAL THERAPY, 2010, 15 : A36 - A37
  • [5] 96 week results from the MONET trial: a randomized comparison of darunavir/ritonavir with versus without nucleoside analogues, for patients with HIV RNA <50 copies/mL at baseline
    Clumeck, Nathan
    Rieger, Armin
    Denes Banhegyi
    Schmidt, Wolfgang
    Hill, Andrew
    Van Delft, Yvonne
    Moecklinghoff, Christiane
    Arribas, Jose
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2011, 66 (08) : 1878 - 1885
  • [6] The PROTEA trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV-1 RNA below 50 copies/mL
    Antinori, Andrea
    Arribas, Jose
    Fehr, Jan
    Girard, Pierre-Marie
    Horban, Andrzej
    Hill, Andrew
    van Delft, Yvon
    Moecklinghoff, Christiane
    Hill, Andrew
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2014, 17 : 24 - 25
  • [7] Three-year evaluation of neuropsychiatric adverse events in the MONET trial of darunavir/ritonavir (DRV/r), with or without nucleoside analogues (NRTIs)
    Winston, A.
    Arribas, J.
    Hill, A.
    van Delft, Y.
    Moecklinghoff, C.
    ANTIVIRAL THERAPY, 2011, 16 : A65 - A65
  • [8] The MONET trial: week 144 analysis of the efficacy of darunavir/ritonavir (DRV/r) monotherapy versus DRV/r plus two nucleoside reverse transcriptase inhibitors, for patients with viral load <50 HIV-1 RNA copies/mL at baseline
    Arribas, J. R.
    Clumeck, N.
    Nelson, M.
    Hill, A.
    van Delft, Y.
    Moecklinghoff, C.
    HIV MEDICINE, 2012, 13 (07) : 398 - 405
  • [9] Neuropsychiatric adverse events and CSF penetration effectiveness (CPE) score in the MONET trial of darunavir/ritonavir (DRV/r), with or without nucleoside analogues (NRTIs)
    Winston, A.
    Arribas, J.
    Hill, A.
    van Delft, Y.
    Moecklinghoff, C.
    ANTIVIRAL THERAPY, 2010, 15 (08) : A69 - A70
  • [10] Neuropsychiatric adverse events and CSF penetration effectiveness (CPE) score in the MONET trial of darunavir/ritonavir (DRV/r), with or without nucleoside analogues (NRTIs)
    Winston, A.
    Arribas, J.
    Hill, A.
    van Delft, Y.
    Moecklinghoff, C.
    ANTIVIRAL THERAPY, 2010, 15 : A69 - A70
12